Progen Pharmaceuticals Limited Company Profile - Aug 09, 2011 by WrightReports

VIEWS: 13 PAGES: 10

Progen Pharmaceuticals Limited (Progen) is a biotechnology company. The Company is engaged in the development and commercialization of small molecule therapeutics for the treatment of cancer. Its activities comprise the research, development, and manufacture of biopharmaceuticals. The Company operates the research and development business segment in Australia. PharmaSynth Pty Ltd (PharmaSynth), a subsidiary of the Company, operates a current good manufacturing practice (cGMP), certified manufacturing facility that provides contract manufacturing services to the biotechnology industry, earning revenues on a fee for service basis. During the fiscal year ended June 30, 2010 (fiscal 2010), contract and consulting services revenues constituted 100% of its consolidated sales revenue.

More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   Progen Pharmaceuticals Limited
                                                                                       440 Wheelers Farms Road
                                                                                       Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in Australian Dollars

                                 Wright Quality Rating:LCNN                                 Key Data

   Progen Pharmaceuticals Limited (Progen) is a biotechnology company. The Company          Ticker:
   is engaged in the development and commercialization of small molecule therapeutics       PGL
   for the treatment of cancer. Its activities comprise the research, development, and
   manufacture of biopharmaceuticals. The Company operates the research and                 2010 Sales:
   development business segment in Australia. PharmaSynth Pty Ltd (PharmaSynth), a
                                                                                            1,973,000
   subsidiary of the Company, operates a current good manufacturing practice (cGMP),
   certified manufacturing facility that provides contract manufacturing services to the
   biotechnology industry, earning revenues on a fee for service basis. During the fiscal   Major Industry:
   year ended June 30, 2010 (fiscal 2010), contract and consulting services revenues        Drugs, Cosmetics & Health
   constituted 100% of its consolidated sales revenue.                                      Care
                       Stock Chart                                   Officers
                                                              Non Executive Chairman        Sub Industry:
                                                                Stuart Bruce James          Ethical Drug Manufacturers

                                                                General Manager &           Country:
                                                                   Secretary                Australia
                                                                    Paul Dixon
                                                                                            Currency:
                                                                                            Australian Dollars

                                                                                            Fiscal Year Ends:
                                                                                            June

                                                                                            Employees
                                                                                            41

                                                                                            Exchanges:
                                                                                            OTC

                                                                                            Share Type:
             Stock Price (8/5/2011): 0.27                                                   Ordinary
              Recent stock performance
                  1 Week       -3.6%
                                                                                            Market Capitalization:
                  4 Weeks      12.5%
                                                                                            6,671,456
                  13 Weeks    -16.9%
                  52 Weeks    -20.6%
  
								
To top